Ellex Medical Lasers gains FDA approval for laser slit lamp

Ellex Medical Lasers has announced today that it has gained US FDA 510(k) approval to market the new Ellex 30XL laser slit lamp, which will be featured at the annual meeting of the American Society of Cataract and Refractive Surgery (ASCRS) beginning April 27th, 2007 in San Diego, CA.

"FDA approval of the 30XL laser slit lamp represents another milestone in Ellex's stated strategy to be the leading brand of lasers to treat glaucoma, cataract and retinal conditions," said Ellex CEO Peter Falzon. "Ellex has invested $12 million over four years to expand our laser product line utilizing expertise gained as an OEM manufacturer of over 12,000 laser systems since 1985."

The 30XL laser slit lamp was designed for use in the ophthalmic clinic setting with the Ellex single or dual port Solitaire green laser photocoagulator and Ellex laser indirect ophthalmoscope (LIO). Including the 30XL laser slit lamp, Ellex provides the industry's most complete line of lasers and accessories used by ophthalmologists to preserve vision and fight blindness.

In addition, the Ellex ASCRS exhibit will feature booth presentations by Dr. Harvey Carter and Dr. Randy Craven on advanced anterior segment laser and ultrasound procedures. And, for the first time, Ellex will exhibit and market the Eye Cubed(TM) ultrasound system alongside their laser product line. The Eye Cubed ultrasound is being integrated into Ellex's product line following the December 2006 acquisition of Innovative Imaging Inc. of Sacramento, California.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Long-term low-dose antiviral treatment reduces eye disease risk from shingles